

## Special Issue

# Photodynamic Therapy in Cancer—Second Edition

### Message from the Guest Editor

This Special Issue, entitled “Photodynamic Therapy of Cancer”, aims to publish the latest research and translational work in the field of PDT in the form of original articles relating to nanodelivery carriers, photochemical and photobiological aspects, targeted drug delivery, tumor image-guided surgery, immunogenic cell death, and PDT-based multimodal therapies of cancer.

---

### Guest Editor

Dr. Shazia Bano

Laboratory of Dr. Tayyaba Hasan, Harvard Medical School, Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA

---

### Deadline for manuscript submissions

30 April 2026



# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9

CiteScore 6.8

Indexed in PubMed



[mdpi.com/si/255517](https://mdpi.com/si/255517)

*Biomedicines*

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/biomedicines)

biomedicines





# Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](http://mdpi.com/journal/biomedicines)

## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

